Raw data are available from: <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138100>.

Introduction {#sec005}
============

Epilepsy is defined as an inherent predisposition of the brain to recurrently generate epileptic seizures \[[@pone.0226575.ref001]\] and affects an estimated 65 million people world-wide \[[@pone.0226575.ref002]\]. Temporal lobe epilepsy (TLE) is the most common subtype amongst the focal epilepsies \[[@pone.0226575.ref003]\], with hippocampal sclerosis being detected in 70% of drug resistant TLE patients \[[@pone.0226575.ref004], [@pone.0226575.ref005]\]. The typical clinical course of the sub-entity, mesial temporal lobe epilepsy with hippocampal sclerosis (mTLE-HS), is characterized by an initial precipitating event (e.g. cerebral trauma, inflammation, prolonged febrile seizure), a seizure-free latency period and finally the onset of spontaneous and progressive seizures \[[@pone.0226575.ref006]\]. This metamorphosis into a brain prone to spontaneous recurrent seizures of progressive nature, also referred to as epileptogenesis \[[@pone.0226575.ref007], [@pone.0226575.ref008]\], is characterized by a plethora of cellular and molecular changes in both neurons and glia \[[@pone.0226575.ref005], [@pone.0226575.ref009]--[@pone.0226575.ref018]\].

One third of people with epilepsy respond inadequately to treatment with the primarily symptom-alleviating antiepileptic drugs of today \[[@pone.0226575.ref019]\], rendering the identification of potential upstream effectors of epileptogenesis and the development of disease modifying antiepileptic drugs a task of upmost importance \[[@pone.0226575.ref020], [@pone.0226575.ref021]\].

DNAm, in the context of this paper, the methylation of CpG nucleotides in the DNA \[[@pone.0226575.ref022]\], plays a primordial role in brain development, cell fate, tissue specific gene expression \[[@pone.0226575.ref022]--[@pone.0226575.ref025]\]. It has further been shown to be modified by neuronal activity \[[@pone.0226575.ref026]\]. Alterations of DNAm in epileptogenesis encompass upregulation of DNA--methyl--transferases, enzymes methylating the DNA base cytosine, in human TLE patients \[[@pone.0226575.ref027]\], genome wide changes in DNAm during epileptogenesis \[[@pone.0226575.ref028], [@pone.0226575.ref029]\], and a later onset of spontaneous seizures in murine epilepsy models under treatment with a DNA-methyl-transferase inhibitor \[[@pone.0226575.ref030]\].

With the dawn of new site- and cell specific epigenetic modulators like modified CRISPR, zinc finger proteins and transcription-activator-like-effectors \[[@pone.0226575.ref031]--[@pone.0226575.ref033]\], the identification of potential genomic sites for antiepileptogenic intervention is of utmost importance.

DNAm in neurons and glial cells is mostly cell specific \[[@pone.0226575.ref034], [@pone.0226575.ref035]\]. Sorting of brain tissue into specific cell types prior to downstream analysis has been applied in previous studies of gene expression \[[@pone.0226575.ref036]--[@pone.0226575.ref038]\] and DNA methylation \[[@pone.0226575.ref039]--[@pone.0226575.ref041]\]. This approach provides information about the cellular origin of observed effects on the epigenome and transcriptome level and an elevated detection sensitivity of more subtle changes in DNAm and GE.

Hypotheses for this study are i) that epileptogenesis affects DNAm and GE in a cell specific manner and ii) that differential methylation (DM) in neurons and glial cells correlates with differential gene expression (DGE). To our knowledge, this is the first study to investigate DNAm and GE changes as well as their possible association in neurons and glia separately, and the first one of its kind conducted in the widely used intracortical mouse model of mTLE \[[@pone.0226575.ref015]\].

Methods {#sec006}
=======

Animals {#sec007}
-------

Adult male C57/BL6N mice (Janvier lab) were acquired at an age of 8 weeks, acclimatized for 4 weeks in a controlled environment (21-23° C, 12h dark/light cycles), 1--4 animals per cage, with water and food available *ad libitum*. All animal procedures were approved by the Norwegian Food Safety Authority (national ethics committee, project number FOTS: 14198) and the Centre for Comparative Medicine, Oslo University Hospital and the University of Oslo.

Intracortical kainic acid mouse model of mTLE {#sec008}
---------------------------------------------

We used deep cortical (juxta hippocampal) kainic acid injection to elicit an initial status epilepticus. The animal model has been described in detail in a separate paper \[[@pone.0226575.ref015]\]. Briefly, mice injected with kainic acid typically (91%) develop chronic epilepsy in a stagewise manner. During the acute stage directly after kainic acid injection, animals undergo a status epilepticus lasting around 4 hours (4.4 +- 2.4 hrs). This stage is followed by a clinically silent latent phase that lasts around 5 days (5+-2.9 days). The first spontaneous seizure at the end of this stage also marks the start of the last, chronic, stage of epileptogenesis, characterized by spontaneous seizures of progressive nature. For kainic acid injections, mice were anesthetized with a mixture of medetomidine (0.3 mg/kg, i.p.) and ketamine (40 mg/kg, i.p.) and kept on a heating blanket. A small craniotomy was performed in a stereotactic frame above the right hippocampus. Then kainic acid (70 nl, 20 mM, Tocris) was injected by a Hamilton pipette (Hamilton Company, NV) at a depth of 1.7 mm at the following coordinates relative to Bregma: anteroposterior −2 mm, lateral +1.5 mm (right). Anesthesia was stopped with atipamezole (300 mg/kg, i.p.). All mice received buprenorphine (0.1mg/kg, s.c.) at 4 and 12 hours after the intervention. Animals in the KA group not displaying convulsive seizures were excluded from further analysis. SH animals underwent the same procedures as described for the KA group, apart from 0,9% NaCl used instead of kainic acid for the intracortical injection.

Tissue collection and pooling {#sec009}
-----------------------------

At 24 hours after status epilepticus, cervical dislocation was performed under anesthesia and right hippocampi were extracted. After extraction, each hemisphere was placed in a 2 mL polypropylene tube, instantly shock frozen in liquid nitrogen, and stored at -80°C. Right hippocampi were pooled in 2 mL tubes from 4 (KA n = 4, S n = 4) or 2 (KA n = 4, S n = 4) mice prior to further processing. The number of mice per group (KA, SH) amounted to 8 mice per group, the number of biological samples to 3 per group (KA, SH). Tissue was kept on dry ice during pooling. See also [S1 Fig](#pone.0226575.s003){ref-type="supplementary-material"}.

Fluorescent Activated Nuclear Sorting (FANS) {#sec010}
--------------------------------------------

A modified version of a nuclear sorting protocol by Jiang *et al*. \[[@pone.0226575.ref042]\] was used to sort into NeuN+ (refered to as neurons) and NeuN- (refered to as glia) nuclei. Immediately after pooling, hippocampi were placed on ice, and 1 mL homogenization buffer was added to each pool. Tissue was homogenized using a GentleMACS dissociator (Miltenyi), and homogenate filtered through a 70 μm filter. A NeuN-negative control sample from adult mouse liver was processed in parallel with the hippocampal samples. Debris was removed by density gradient centrifugation, using Debris Removal Solution (Miltenyi), and nuclear pellets were resuspended in 100 μL incubation buffer per one million nuclei. Anti-NeuN Alexa Fluor488 (Merck Millipore) was added to each sample to a final concentration of 0.1 μg/mL, and samples incubated for 1 h on ice in a light protected environment. Sorting of nuclei was performed on a FACSAria (BD Biosciences). Propidium iodide (PI) was added prior to sorting, and the following strategy was used for gating ([S2 Fig](#pone.0226575.s004){ref-type="supplementary-material"}): 1) A nuclear gate was defined by PI-positive events. 2) Aggregated nuclei were excluded in a dot plot using the pulse width of side scatter (SSC-w) versus the pulse area of forward scatter (FSC-a). 3) NeuN-negative gate was drawn based on signal from anti-NeuN stained liver sample. NeuN-positive and NeuN-negative hippocampi nuclei were sorted into tubes, and nuclei pelleted by centrifugation. Pellets were resuspended in lysis buffer for downstream DNA and RNA isolation. A full description of the FANS procedure is given in [S1 Supporting Information](#pone.0226575.s002){ref-type="supplementary-material"}.

Isolation of DNA and total RNA from sorted nuclei {#sec011}
-------------------------------------------------

DNA was extracted from sorted nuclei with MasterPure Complete DNA and RNA Purification Kit (Epicentre), DNA purity was assessed on NanoDrop, and DNA concentration measured on Qubit (DNA HS assay). Further details are available in [S1 Supporting Information](#pone.0226575.s002){ref-type="supplementary-material"}. Lysates were thawed on ice and total RNA extracted with mirVana miRNA Isolation Kit (Ambion). Up-concentration was performed using RNA Clean & Concentrator-5 kit (Zymo Research). RNA concentration and integrity were assessed on Bioanalyzer with the RNA Pico Kit (Agilent Technologies). Further details are found in [S1 Supporting Information](#pone.0226575.s002){ref-type="supplementary-material"}.

RRBS {#sec012}
----

A modified version of the gel-free protocol by Boyle *et al*. \[[@pone.0226575.ref043]\] was used for RRBS library preparation. The main changes to the protocol were inclusion of a two-sided size selection prior to bisulfite conversion, and sample pooling performed after completion of single libraries. A full description of the RRBS library prep and sequencing is given in [S1 Supporting Information](#pone.0226575.s002){ref-type="supplementary-material"}. Libraries were subjected to either 75 bp single read sequencing on NextSeq500 (Illumina), or 150 bp single read sequencing on HiSeq2500 (Illumina). For sequencing on NextSeq500, a pool of 14 libraries were run twice, with 50% PhiX spike-in at each run. On HiSeq2500, pools of 15 libraries were sequenced over two lanes, using 10% PhiX spike-in.

High throughput mRNAseq {#sec013}
-----------------------

SMART-Seqv4 Ultra Low InputRNA Kit for Sequencing (Takara Bio) was used to amplify mRNA from total RNA, and the resulting cDNA was used as input in library preparation with ThruPlex DNAseq Kit (Rubicon Genomics). See [S1 Supporting Information](#pone.0226575.s002){ref-type="supplementary-material"} for details regarding cDNA synthesis and library preparation. Libraries were sequenced on NextSeq500 (75 bp single read), or HiSeq3000 (150 bp paired end). On NextSeq500, 12 libraries were pooled for one sequencing-run. The remaining 27 libraries were sequenced in one pool over three lanes on HiSeq3000.

Computational methods {#sec014}
---------------------

### RRBS- and mRNAseq-post processing {#sec015}

Post-processing included trimming of reads using Trim Galore! v0.4.3 with parameters \"---rrbs---illumina\" and quality control with FastQC. Alignment to the reference mouse genome mm10 was performed with Bismark v0.20, powered by bowtie2. Quality metrics were collected from the resulting BAM files using the Picard tool CollectRrbsMetrics v2.18.15.

Alignment of the mRNAseq reads was accomplished with the Subread package through its R interface Rsubread, after trimming with Trim Galore! v0.4.3. Quality control of the resulting BAM files was undertaken with CollectRnaSeqMetrics from Picard v2.18.15. Uniquely mapped reads were assigned to genes and counted by the featureCounts function of Rsubread, using default parameters. As reference for the gene assignment we used release M16 of the comprehensive gene annotation of mm10 available from GENCODE. Only RNA aligning to mRNA regions was used for further analysis.

### Annotation {#sec016}

The mouse genome build mm10 was used as reference in all analyses. Only autosomal data were analyzed. Coordinates of genes, exons and introns were taken from GENCODE\'s comprehensive annotation ([www.gencodegenes.org/mouse/release_M16.html](http://www.gencodegenes.org/mouse/release_M16.html)). The R package annotatr \[[@pone.0226575.ref044]\] was used to bioinformatically link CpG sites to the gene annotations.

Using predefined genomic features within annotatr \[[@pone.0226575.ref044]\], the promoter region for any gene was defined as the segment from -1kb upstream to the transcription start site and the upstream region from -5 kb to -1 kb, where negative numbers indicate positions upstream of transcription start site.

Statistical methods {#sec017}
-------------------

### Analysis of DGE {#sec018}

The R package edgeR \[[@pone.0226575.ref045]\] was used to identify differentially expressed genes in the mRNAseq (mRNA) data set. The data from neuronal and glia cells were treated separately, contrasting KA versus SH samples in each case. Genes without official HGNC symbol were excluded from the analysis. Genes with low read counts were also removed, using the edgeR function filterByExpr with default parameters. After normalization to adjust for different library sizes (calcNormFactors) we followed a standard edgeR workflow to fit a quasi-likelihood negative binomial generalized log-linear model to the count data, and to perform the subsequent statistical analysis. A false discovery rate (FDR) approach was adopted to account for multiple testing, with a significance threshold of FDR 25%.

### Analysis of DM {#sec019}

To identify loci exhibiting differential methylation between KA and SH samples, we adopted the edgeR workflow for RRBS data recently published by the edgeR authors \[[@pone.0226575.ref046]\]. Briefly, this approach entails treating the methylated and unmethylated counts at each locus as independent variables following a negative binomial distribution. As in the DGE analysis, DM analysis was carried out separately for neurons and glia cells, with an FDR of 25% as threshold for statistical significance. Before the analysis, filters were applied to all CpG sites where more than 10% of the samples had either very low coverage (\< 8 reads) or excessively high coverage (\> 99.5 quantile across all sites and samples). The DM analysis was performed both at the level of individual CpG sites, and in aggregated form within pre-defined genomic features: upstream, promoter, UTR5, exons, introns, gene body (i.e. the union of all exons and introns of a specific gene) and UTR3. For the aggregated analysis the input was the mean counts across all covered CpG\'s within the region.

### Combined DM and DGE analysis {#sec020}

For each genomic feature (upstream, promoter, UTR5, exon, intron, gene body, UTR3), a combined analysis of DGE and DM was performed in order to unveil genes for which both methylation and gene expression differed significantly between the two groups. To reduce the statistical noise, the DGE analysis was reanalyzed for each genomic feature type, using only the relevant subset of the data. Specifically, for each genomic feature type, only the genes present in the aggregated DM data set were kept in the DGE analysis. Co-incidence of DGE and DM was declared for features surviving an FDR cutoff of 25% in both analyses.

### Functional enrichment analysis {#sec021}

Enrichment analyses of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were performed with the goana and kegga functions of edgeR, with the parameter species = \"Mm\". These functions conduct overlap tests for the up- and down-regulated DE genes, and for the genes overlapping DMRs.

Quality control {#sec022}
---------------

### Bisulfite conversion rate estimation {#sec023}

The conversion rate estimate computed by Picard/CollectRrbsMetrics is based on the conversion of non-CpG cytosines. As methylation of non-CpG cytosines is non-negligible in neuronal cells, this may bias the results. To account for this, we also performed an alternative estimate of the conversion rates directly from the untrimmed fastq files, by checking the methylation status specifically on the (unmethylated) cytosines added in the end-repair step of the RRBS preparation (private bash script). See [S1 Supporting Information](#pone.0226575.s002){ref-type="supplementary-material"} for further information of bisulfite conversion rate.

### Multidimensional scaling {#sec024}

In order to validate our cell sorting procedures, and look for outliers among the samples, multidimensional scaling (MDS) plots were produced for the mRNAseq and RRBS data sets. The MDS computations were done by the plotMDS function of edgeR, selecting the top 100 most variable loci. The actual plots were created with ggplot2 \[[@pone.0226575.ref047]\].

### Expression of neuronal and glial genes in NeuN+ and NeuN- fraction {#sec025}

Normalized counts for expression of neuronal (*RBFOX3*), glial (*ALDHL1L1*, *CX3CR1*, *MBP)*, *pericytal (PDGFRB) and endothelial (PECAM1*) genes were used to visualize enrichment of neurons in the NeuN+ fraction and glia in the NeuN- fraction.

Selection of relevant GO and KEGG terms {#sec026}
---------------------------------------

Relevant (Tables [1](#pone.0226575.t001){ref-type="table"} and [2](#pone.0226575.t002){ref-type="table"}) and epilepsy-relevant ([Fig 2](#pone.0226575.g002){ref-type="fig"}) GO and KEGG terms in neurons and glia were selected manually based on reviews on the subject \[[@pone.0226575.ref009]\] and personal knowledge. The list of GO and KEGG terms derived from our DGE analysis (for a full list see [S1 Table](#pone.0226575.s001){ref-type="supplementary-material"}) was manually filtered for specific terms and relevant up-/downregulated genes within these terms in neurons and glia selected for presentation.

10.1371/journal.pone.0226575.t001

###### Differentially expressed genes in neurons at 24 hours post injection in the intracortical kainic acid model of mTLE.
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  Differentially expressed genes in neurons                         
  ------------------------------------------- ----------- --------- --------------------------------------------------------------------------
  **Upregulated genes (N = 135)**                                   
  **Gene symbol**                             **logFC**   **FDR**   **Gene description**
  Acan                                        3,94        0,000     aggrecan
  Sdc1                                        3,60        0,001     syndecan 1
  Inhba                                       4,12        0,001     inhibin beta-A
  Socs3                                       4,21        0,001     suppressor of cytokine signaling 3
  Timp1                                       5,38        0,007     tissue inhibitor of metalloproteinase 1
  Megf11                                      2,25        0,011     multiple EGF-like-domains 11
  Nptx2                                       3,61        0,011     neuronal pentraxin 2
  Hspa1a                                      5,46        0,011     heat shock protein 1A
  Fgl2                                        3,07        0,011     fibrinogen-like protein 2
  Col27a1                                     3,22        0,012     collagen, type XXVII, alpha 1
  Mapk4                                       2,28        0,012     mitogen-activated protein kinase 4
  Cd1d1                                       2,94        0,018     CD1d1 antigen
  Sik1                                        2,31        0,019     salt inducible kinase 1
  Hspa1b                                      4,82        0,019     heat shock protein 1B
  Tnc                                         2,08        0,019     tenascin C
  Ptgs2                                       3,11        0,019     prostaglandin-endoperoxide synthase 2
  Gipr                                        3,72        0,019     gastric inhibitory polypeptide receptor
  Trib1                                       2,46        0,019     tribbles pseudokinase 1
  Tpbg                                        2,10        0,019     trophoblast glycoprotein
  Lhfp                                        1,71        0,019     lipoma HMGIC fusion partner
  Fosb                                        3,32        0,019     FBJ osteosarcoma oncogene B
  Arc                                         2,40        0,020     activity regulated cytoskeletal-associated protein
  Fosl2                                       2,26        0,020     fos-like antigen 2
  Gadd45g                                     2,54        0,027     growth arrest and DNA-damage-inducible 45 gamma
  Pcdh11x                                     2,26        0,027     protocadherin 11 X-linked
  Pmepa1                                      2,30        0,027     prostate transmembrane protein, androgen induced 1
  Stk40                                       2,03        0,027     serine/threonine kinase 40
  Pde6b                                       2,91        0,027     phosphodiesterase 6B, cGMP, rod receptor, beta polypeptide
  Wisp1                                       2,09        0,027     WNT1-inducible-signaling pathway protein 1
  9330188P03Rik                               3,35        0,027     RIKEN cDNA 9330188P03 gene
  Pappa                                       2,89        0,027     pregnancy-associated plasma protein A
  Hspb1                                       4,00        0,027     heat shock protein 1
  Atf3                                        4,52        0,029     activating transcription factor 3
  Tll1                                        3,71        0,029     tolloid-like
  Sulf1                                       1,57        0,031     sulfatase 1
  Lbh                                         3,01        0,034     limb-bud and heart
  Nedd9                                       1,51        0,035     neural precursor cell expressed, developmentally down-regulated gene 9
  Parp3                                       2,93        0,035     poly (ADP-ribose) polymerase family, member 3
  Rrad                                        4,89        0,035     Ras-related associated with diabetes
  Trh                                         6,22        0,035     thyrotropin releasing hormone
  4931440P22Rik                               1,70        0,037     RIKEN cDNA 4931440P22 gene
  Cyr61                                       2,90        0,037     Cysteine-rich angiogenic inducer 61 
  Fos                                         2,89        0,037     FBJ osteosarcoma oncogene
  Cgref1                                      2,08        0,037     cell growth regulator with EF hand domain 1
  Angptl4                                     2,49        0,037     angiopoietin-like 4
  Srxn1                                       2,09        0,037     sulfiredoxin 1 homolog (S. cerevisiae)
  Vim                                         2,84        0,039     vimentin
  Vgf                                         2,37        0,041     VGF nerve growth factor inducible
  Plpp4                                       2,33        0,043     phospholipid phosphatase 4
  Clcf1                                       3,01        0,045     cardiotrophin-like cytokine factor 1
  Zbtb46                                      1,58        0,048     zinc finger and BTB domain containing 46
  Egr2                                        2,18        0,052     early growth response 2
  Bach1                                       1,72        0,052     BTB and CNC homology 1, basic leucine zipper transcription factor 1
  Samd4                                       1,90        0,052     sterile alpha motif domain containing 4
  Rgs4                                        2,24        0,053     regulator of G-protein signaling 4
  Cdkn1a                                      2,86        0,053     cyclin-dependent kinase inhibitor 1A (P21)
  Adra1a                                      1,92        0,054     adrenergic receptor, alpha 1a
  Csrnp1                                      2,36        0,054     cysteine-serine-rich nuclear protein 1
  Gal                                         3,64        0,054     galanin and GMAP prepropeptide
  Npas4                                       3,24        0,055     neuronal PAS domain protein 4
  Sbno2                                       2,21        0,055     strawberry notch 2
  Fndc9                                       3,19        0,061     fibronectin type III domain containing 9
  Syndig1l                                    1,94        0,063     synapse differentiation inducing 1 like
  Gpr3                                        1,97        0,075     G-protein coupled receptor 3
  Fam129b                                     1,40        0,075     family with sequence similarity 129, member B
  Sv2c                                        2,56        0,075     synaptic vesicle glycoprotein 2c
  Adam19                                      1,62        0,081     a disintegrin and metallopeptidase domain 19 (meltrin beta)
  Pim1                                        2,43        0,083     proviral integration site 1
  Bag3                                        1,81        0,083     BCL2-associated athanogene 3
  Sphk1                                       2,57        0,086     sphingosine kinase 1
  Mapkapk3                                    1,97        0,086     mitogen-activated protein kinase-activated protein kinase 3
  Zfp36                                       2,50        0,086     zinc finger protein 36
  Cdh4                                        1,45        0,087     cadherin 4
  Kdm6b                                       1,57        0,090     KDM1 lysine (K)-specific demethylase 6B
  Emp1                                        2,49        0,091     epithelial membrane protein 1
  Spp1                                        3,14        0,091     secreted phosphoprotein 1
  Sorcs3                                      2,28        0,094     sortilin-related VPS10 domain containing receptor 3
  Cd1d2                                       3,29        0,097     CD1d2 antigen
  Prex1                                       2,06        0,101     phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1
  Pros1                                       2,10        0,101     protein S (alpha)
  Uck2                                        1,35        0,101     uridine-cytidine kinase 2
  Plce1                                       1,40        0,101     phospholipase C, epsilon 1
  Tgfb1i1                                     1,66        0,101     transforming growth factor beta 1 induced transcript 1
  Crispld2                                    2,18        0,117     cysteine-rich secretory protein LCCL domain containing 2
  Frrs1                                       1,87        0,117     ferric-chelate reductase 1
  Blnk                                        2,81        0,118     B cell linker
  1700071M16Rik                               1,68        0,119     RIKEN cDNA 1700071M16 gene
  Rgs20                                       1,74        0,119     regulator of G-protein signaling 20
  Ier2                                        2,17        0,120     immediate early response 2
  Itprip                                      1,88        0,130     inositol 1,4,5-triphosphate receptor interacting protein
  Smad7                                       1,83        0,130     SMAD family member 7
  Svil                                        1,52        0,130     supervillin
  Serinc2                                     1,79        0,136     serine incorporator 2
  Cemip2                                      1,44        0,154     cell migration inducing hyaluronidase 2
  Mir132                                      3,39        0,154     microRNA 132
  Pear1                                       3,01        0,164     platelet endothelial aggregation receptor 1
  Zdhhc22                                     1,85        0,167     zinc finger, DHHC-type containing 22
  Medag                                       2,23        0,167     mesenteric estrogen dependent adipogenesis
  Amotl1                                      1,71        0,175     angiomotin-like 1
  Serpina3i                                   2,75        0,178     serine (or cysteine) peptidase inhibitor, clade A, member 3I
  Ptgs1                                       2,01        0,178     prostaglandin-endoperoxide synthase 1
  Ifit1                                       2,33        0,178     interferon-induced protein with tetratricopeptide repeats 1
  Kcnip3                                      1,67        0,178     Kv channel interacting protein 3, calsenilin
  Odc1                                        1,57        0,178     ornithine decarboxylase, structural 1
  Igsf9b                                      2,27        0,178     immunoglobulin superfamily, member 9B
  Homer1                                      1,49        0,179     homer scaffolding protein 1
  Spred1                                      1,62        0,184     sprouty protein with EVH-1 domain 1, related sequence
  Samd11                                      2,19        0,186     sterile alpha motif domain containing 11
  Cdk18                                       1,98        0,186     cyclin-dependent kinase 18
  Scd4                                        2,01        0,191     stearoyl-coenzyme A desaturase 4
  Dgat2l6                                     3,15        0,191     diacylglycerol O-acyltransferase 2-like 6
  Dusp4                                       1,88        0,191     dual specificity phosphatase 4
  Anxa2                                       2,12        0,191     annexin A2
  Serpina3n                                   1,85        0,191     serine (or cysteine) peptidase inhibitor, clade A, member 3N
  Tspan9                                      1,68        0,191     tetraspanin 9
  Eva1b                                       2,00        0,191     eva-1 homolog B (C. elegans)
  Btc                                         2,40        0,191     betacellulin, epidermal growth factor family member
  Acvr1c                                      1,91        0,193     activin A receptor, type IC
  Rara                                        1,54        0,194     retinoic acid receptor, alpha
  St8sia2                                     2,11        0,195     ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2
  Tm4sf1                                      2,49        0,195     transmembrane 4 superfamily member 1
  Cdh22                                       1,77        0,195     cadherin 22
  Gfra1                                       1,50        0,202     glial cell line derived neurotrophic factor family receptor alpha 1
  Itga5                                       2,11        0,205     integrin alpha 5 (fibronectin receptor alpha)
  C2cd4b                                      2,11        0,206     C2 calcium-dependent domain containing 4B
  Rasa4                                       1,84        0,220     RAS p21 protein activator 4
  Mapk6                                       1,51        0,223     mitogen-activated protein kinase 6
  Egr4                                        1,91        0,227     early growth response 4
  Itpkc                                       1,84        0,227     inositol 1,4,5-trisphosphate 3-kinase C
  Ptx3                                        2,72        0,235     pentraxin related gene
  Tnfrsf12a                                   1,87        0,235     tumor necrosis factor receptor superfamily, member 12a
  Drd1                                        1,82        0,246     dopamine receptor D1
  **Downregulated genes (N = 15)**                                  
  **Gene symbol**                             **logFC**   **FDR**   **Gene description**
  Cxcl12                                      -1,96       0,027     chemokine (C-X-C motif) ligand 12
  Ogn                                         -2,71       0,029     osteoglycin
  Plk5                                        -2,79       0,040     polo like kinase 5
  Cys1                                        -1,85       0,041     cystin 1
  Capn3                                       -2,14       0,052     calpain 3
  Echdc2                                      -1,77       0,079     enoyl Coenzyme A hydratase domain containing 2
  Cyp7b1                                      -2,28       0,097     cytochrome P450, family 7, subfamily b, polypeptide 1
  Gm12216                                     -1,65       0,101     predicted gene 12216
  Gstm6                                       -1,57       0,161     glutathione S-transferase, mu 6
  Cd34                                        -1,63       0,167     CD34 antigen
  Stxbp6                                      -1,51       0,186     syntaxin binding protein 6 (amisyn)
  Crlf1                                       -1,97       0,194     cytokine receptor-like factor 1
  Macrod1                                     -1,52       0,195     MACRO domain containing 1
  Gm35339                                     -1,43       0,195     predicted gene, 35339
  6330420H09Rik                               -2,15       0,216     RIKEN cDNA 6330420H09 gene

Differentially expressed genes in neurons (FDR \< 0.25); logFC = log fold change; FDR = false discovery rate.

10.1371/journal.pone.0226575.t002

###### Differentially expressed genes in glia at 24 hours post injection in the intracortical kainic acid model of mTLE.
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  Differentially expressed genes in glia                         
  ---------------------------------------- ----------- --------- -----------------------------------------------------------------------------------------
  **Upregulated genes (N = 147)**                                
  **Gene symbol**                          **logFC**   **FDR**   **Gene description**
  Serpina3n                                4,23        0,001     serine (or cysteine) peptidase inhibitor, clade A, member 3N
  Thbd                                     2,93        0,001     thrombomodulin
  Ch25h                                    5,14        0,001     cholesterol 25-hydroxylase
  Lilr4b                                   4,88        0,002     leukocyte immunoglobulin-like receptor, subfamily B, member 4B
  Gm3448                                   3,23        0,003     predicted gene 3448
  Ucn2                                     8,54        0,003     urocortin 2
  Ccl2                                     3,45        0,003     chemokine (C-C motif) ligand 2
  Socs3                                    3,66        0,004     suppressor of cytokine signaling 3
  Ier5l                                    2,55        0,005     immediate early response 5-like
  Calca                                    4,68        0,005     calcitonin/calcitonin-related polypeptide, alpha
  Sphk1                                    3,89        0,005     sphingosine kinase 1
  Ecm1                                     2,40        0,005     extracellular matrix protein 1
  Emp1                                     3,67        0,005     epithelial membrane protein 1
  Ahnak2                                   3,87        0,005     AHNAK nucleoprotein 2
  Spp1                                     4,71        0,005     secreted phosphoprotein 1
  S1pr3                                    3,16        0,005     sphingosine-1-phosphate receptor 3
  Fn1                                      2,64        0,007     fibronectin 1
  Fgl2                                     2,97        0,008     fibrinogen-like protein 2
  Timp1                                    4,60        0,008     tissue inhibitor of metalloproteinase 1
  Tm4sf1                                   4,06        0,008     transmembrane 4 superfamily member 1
  Rasgef1c                                 3,04        0,009     RasGEF domain family, member 1C
  Ifit3                                    2,69        0,010     interferon-induced protein with tetratricopeptide repeats 3
  Vgf                                      2,83        0,010     VGF nerve growth factor inducible
  Il11                                     3,79        0,012     interleukin 11
  Itga5                                    3,16        0,014     integrin alpha 5 (fibronectin receptor alpha)
  Iigp1                                    3,09        0,015     interferon inducible GTPase 1
  Hmga1b                                   2,26        0,015     high mobility group AT-hook 1B
  Gadd45g                                  2,59        0,015     growth arrest and DNA-damage-inducible 45 gamma
  Tnc                                      2,01        0,015     tenascin C
  Cd44                                     3,16        0,015     CD44 antigen
  Gpr151                                   3,26        0,017     G protein-coupled receptor 151
  Ier3                                     2,44        0,020     immediate early response 3
  Tnfrsf12a                                2,69        0,020     tumor necrosis factor receptor superfamily, member 12a
  Sv2c                                     3,05        0,021     synaptic vesicle glycoprotein 2c
  Rasl11a                                  1,99        0,021     RAS-like, family 11, member A
  Klk9                                     3,23        0,021     kallikrein related-peptidase 9
  Btc                                      3,29        0,024     betacellulin, epidermal growth factor family member
  Cebpd                                    1,95        0,025     CCAAT/enhancer binding protein (C/EBP), delta
  Nptx2                                    2,91        0,025     neuronal pentraxin 2
  Adam8                                    3,04        0,025     a disintegrin and metallopeptidase domain 8
  Slc39a14                                 2,07        0,025     solute carrier family 39 (zinc transporter), member 14
  Inhba                                    2,61        0,025     inhibin beta-A
  Cdh22                                    2,38        0,025     cadherin 22
  Fos                                      2,95        0,026     FBJ osteosarcoma oncogene
  Rhoj                                     3,00        0,027     ras homolog family member J
  Lilrb4a                                  4,02        0,027     leukocyte immunoglobulin-like receptor, subfamily B, member 4A
  Cd300lf                                  3,60        0,028     CD300 molecule like family member F
  Gadd45b                                  3,35        0,030     growth arrest and DNA-damage-inducible 45 beta
  Cacng5                                   2,10        0,030     calcium channel, voltage-dependent, gamma subunit 5
  Ifi204                                   4,09        0,032     interferon activated gene 204
  Dab2                                     2,15        0,036     disabled 2, mitogen-responsive phosphoprotein
  Myc                                      2,30        0,036     myelocytomatosis oncogene
  Ifi207                                   3,11        0,043     interferon activated gene 207
  Parp3                                    2,74        0,044     poly (ADP-ribose) polymerase family, member 3
  Hspb1                                    3,54        0,046     heat shock protein 1
  Trib1                                    2,04        0,047     tribbles pseudokinase 1
  Rasip1                                   2,30        0,049     Ras interacting protein 1
  Egr2                                     2,12        0,058     early growth response 2
  Lpl                                      1,88        0,058     lipoprotein lipase
  Tubb6                                    2,19        0,058     tubulin, beta 6 class V
  Tpbg                                     1,72        0,058     trophoblast glycoprotein
  Msr1                                     3,41        0,058     macrophage scavenger receptor 1
  Sbno2                                    2,17        0,058     strawberry notch 2
  Gcnt2                                    2,42        0,061     glucosaminyl (N-acetyl) transferase 2, I-branching enzyme
  Fosb                                     2,69        0,061     FBJ osteosarcoma oncogene B
  Serpine1                                 3,97        0,064     serine (or cysteine) peptidase inhibitor, clade E, member 1
  Oasl2                                    2,47        0,064     2\'-5\' oligoadenylate synthetase-like 2
  Srxn1                                    1,89        0,065     sulfiredoxin 1 homolog (S. cerevisiae)
  Ptgs2                                    2,43        0,066     prostaglandin-endoperoxide synthase 2
  Slc10a6                                  3,88        0,070     solute carrier family 10 (sodium/bile acid cotransporter family), member 6
  Ahnak                                    1,95        0,072     AHNAK nucleoprotein (desmoyokin)
  Nedd9                                    1,33        0,073     neural precursor cell expressed, developmentally down-regulated gene 9
  Rai14                                    1,61        0,074     retinoic acid induced 14
  Layn                                     1,95        0,075     layilin
  Col16a1                                  2,51        0,076     collagen, type XVI, alpha 1
  Atp10a                                   2,07        0,078     ATPase, class V, type 10A
  Fstl4                                    1,87        0,078     follistatin-like 4
  Wwtr1                                    1,58        0,080     WW domain containing transcription regulator 1
  Gal                                      3,44        0,081     galanin and GMAP prepropeptide
  Mx1                                      3,40        0,081     MX dynamin-like GTPase 1
  Hmga1                                    2,18        0,091     high mobility group AT-hook 1
  Irgm1                                    1,56        0,091     immunity-related GTPase family M member 1
  Odc1                                     1,69        0,092     ornithine decarboxylase, structural 1
  Gldn                                     3,04        0,093     gliomedin
  Egr1                                     2,33        0,094     early growth response 1
  Cchcr1                                   1,58        0,094     coiled-coil alpha-helical rod protein 1
  Junb                                     2,29        0,102     jun B proto-oncogene
  Slc5a3                                   1,82        0,102     solute carrier family 5 (inositol transporters), member 3
  Socs2                                    1,76        0,102     suppressor of cytokine signaling 2
  Il4ra                                    1,81        0,102     interleukin 4 receptor, alpha
  Irf7                                     2,39        0,104     interferon regulatory factor 7
  Nlrc5                                    2,21        0,104     NLR family, CARD domain containing 5
  Ptx3                                     2,99        0,105     pentraxin related gene
  Fgf18                                    2,32        0,107     fibroblast growth factor 18
  Ifit3b                                   2,41        0,111     interferon-induced protein with tetratricopeptide repeats 3B
  Strip2                                   1,74        0,115     striatin interacting protein 2
  Has2                                     3,19        0,116     hyaluronan synthase 2
  Mir212                                   4,52        0,117     microRNA 212
  Flnc                                     3,71        0,118     filamin C, gamma
  Map3k6                                   2,39        0,124     mitogen-activated protein kinase kinase kinase 6
  Timeless                                 1,39        0,124     timeless circadian clock 1
  Itga7                                    1,38        0,132     integrin alpha 7
  Bcl3                                     3,83        0,134     B cell leukemia/lymphoma 3
  Snhg15                                   1,56        0,134     small nucleolar RNA host gene 15
  Ccl12                                    2,59        0,142     chemokine (C-C motif) ligand 12
  Mamstr                                   2,09        0,142     MEF2 activating motif and SAP domain containing transcriptional regulator
  Clcf1                                    2,36        0,142     cardiotrophin-like cytokine factor 1
  Bdnf                                     1,81        0,142     brain derived neurotrophic factor
  Ier2                                     2,03        0,142     immediate early response 2
  Rnf138rt1                                5,32        0,149     ring finger protein 138, retrogene 1
  Fosl2                                    1,59        0,152     fos-like antigen 2
  Slfn10-ps                                2,78        0,160     schlafen 10, pseudogene
  Amotl1                                   1,65        0,164     angiomotin-like 1
  Mir132                                   3,30        0,174     microRNA 132
  Serpina3i                                2,64        0,174     serine (or cysteine) peptidase inhibitor, clade A, member 3I
  Hmox1                                    1,87        0,174     heme oxygenase 1
  Lrtm2                                    1,62        0,175     leucine-rich repeats and transmembrane domains 2
  Spred3                                   1,72        0,175     sprouty-related EVH1 domain containing 3
  Vmn1r15                                  6,73        0,175     vomeronasal 1 receptor 15
  Rtp4                                     1,91        0,177     receptor transporter protein 4
  Rnf125                                   2,28        0,177     ring finger protein 125
  Slfn2                                    2,93        0,182     schlafen 2
  Mchr1                                    1,73        0,185     melanin-concentrating hormone receptor 1
  Piezo2                                   1,68        0,185     piezo-type mechanosensitive ion channel component 2
  Anxa2                                    2,01        0,185     annexin A2
  Gpd1                                     1,68        0,190     glycerol-3-phosphate dehydrogenase 1 (soluble)
  Cyr61                                    2,08        0,194     Cysteine-rich angiogenic inducer 61
  Plaur                                    2,39        0,194     plasminogen activator, urokinase receptor
  Kdm6b                                    1,32        0,201     KDM1 lysine (K)-specific demethylase 6B
  Ifit1                                    2,11        0,201     interferon-induced protein with tetratricopeptide repeats 1
  Itga2b                                   1,93        0,202     integrin alpha 2b
  Fgfr4                                    2,25        0,202     fibroblast growth factor receptor 4
  Bst2                                     2,06        0,202     bone marrow stromal cell antigen 2
  Gm6225                                   2,35        0,207     predicted gene 6225
  Cbln4                                    1,60        0,208     cerebellin 4 precursor protein
  Serpina3m                                2,79        0,216     serine (or cysteine) peptidase inhibitor, clade A, member 3M
  Akap12                                   1,34        0,218     A kinase (PRKA) anchor protein (gravin) 12
  Sdc1                                     1,59        0,219     syndecan 1
  Ndst1                                    1,59        0,219     N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1
  Npas4                                    2,45        0,221     neuronal PAS domain protein 4
  Tspan4                                   1,89        0,226     tetraspanin 4
  Klk6                                     2,76        0,226     kallikrein related-peptidase 6
  Cxcl10                                   2,90        0,226     chemokine (C-X-C motif) ligand 10
  Col7a1                                   1,75        0,227     collagen, type VII, alpha 1
  Plce1                                    1,17        0,237     phospholipase C, epsilon 1
  Peak1                                    1,41        0,238     pseudopodium-enriched atypical kinase 1
  Itga1                                    1,36        0,245     integrin alpha 1
  **Downregulated genes (N = 15)**                               
  **Gene symbol**                          **logFC**   **FDR**   **Gene description**
  Aifm3                                    -2,53       0,005     apoptosis-inducing factor, mitochondrion-associated 3
  Sowaha                                   -2,14       0,005     sosondowah ankyrin repeat domain family member A
  Gdpd2                                    -2,73       0,012     glycerophosphodiester phosphodiesterase domain containing 2
  Btbd17                                   -2,36       0,015     BTB (POZ) domain containing 17
  Slc2a5                                   -2,59       0,015     solute carrier family 2 (facilitated glucose transporter), member 5
  Pcx                                      -2,11       0,016     pyruvate carboxylase
  Hapln1                                   -2,63       0,025     hyaluronan and proteoglycan link protein 1
  Shroom2                                  -2,28       0,026     shroom family member 2
  Gpr12                                    -2,22       0,039     G-protein coupled receptor 12
  Ccdc13                                   -1,80       0,046     coiled-coil domain containing 13
  Fn3k                                     -2,03       0,049     fructosamine 3 kinase
  P2ry12                                   -2,57       0,053     purinergic receptor P2Y, G-protein coupled 12
  Cygb                                     -1,88       0,053     cytoglobin
  Ankub1                                   -2,23       0,060     ankrin repeat and ubiquitin domain containing 1
  Siglech                                  -2,16       0,061     sialic acid binding Ig-like lectin H
  Itpka                                    -1,70       0,061     inositol 1,4,5-trisphosphate 3-kinase A
  Traf4                                    -1,81       0,065     TNF receptor associated factor 4
  Hpca                                     -1,84       0,074     hippocalcin
  Ppp1r1b                                  -1,75       0,077     protein phosphatase 1, regulatory inhibitor subunit 1B
  Nkain4                                   -2,55       0,077     Na+/K+ transporting ATPase interacting 4
  Folh1                                    -2,24       0,077     folate hydrolase 1
  Kctd4                                    -2,09       0,081     potassium channel tetramerisation domain containing 4
  Gstm6                                    -1,67       0,083     glutathione S-transferase, mu 6
  Shisa8                                   -2,21       0,091     shisa family member 8
  2810468N07Rik                            -2,22       0,092     RIKEN cDNA 2810468N07 gene
  Abca9                                    -1,97       0,092     ATP-binding cassette, sub-family A (ABC1), member 9
  Paqr7                                    -1,93       0,099     progestin and adipoQ receptor family member VII
  Chn1                                     -1,71       0,099     chimerin 1
  Ntsr2                                    -2,14       0,105     neurotensin receptor 2
  Myh14                                    -1,76       0,105     myosin, heavy polypeptide 14
  Nwd1                                     -1,82       0,108     NACHT and WD repeat domain containing 1
  Fam234a                                  -1,77       0,109     family with sequence similarity 234, member A
  Susd5                                    -1,88       0,116     sushi domain containing 5
  Faah                                     -1,50       0,117     fatty acid amide hydrolase
  Tppp3                                    -1,76       0,124     tubulin polymerization-promoting protein family member 3
  Abca6                                    -1,46       0,124     ATP-binding cassette, sub-family A (ABC1), member 6
  Gnai1                                    -1,90       0,134     guanine nucleotide binding protein (G protein), alpha inhibiting 1
  Cfap100                                  -1,48       0,135     cilia and flagella associated protein 100
  Grm3                                     -2,01       0,142     glutamate receptor, metabotropic 3
  Phgdh                                    -1,66       0,149     3-phosphoglycerate dehydrogenase
  Selplg                                   -2,14       0,152     selectin, platelet (p-selectin) ligand
  Epn2                                     -1,61       0,171     epsin 2
  2900052N01Rik                            -2,06       0,174     RIKEN cDNA 2900052N01 gene
  Rlbp1                                    -1,78       0,175     retinaldehyde binding protein 1
  Pantr1                                   -1,72       0,175     POU domain, class 3, transcription factor 3 adjacent noncoding transcript 1
  Nat8f4                                   -1,42       0,175     N-acetyltransferase 8 (GCN5-related) family member 4
  Plk5                                     -2,14       0,175     polo like kinase 5
  Nat8f1                                   -1,91       0,175     N-acetyltransferase 8 (GCN5-related) family member 1
  1700066M21Rik                            -1,65       0,175     RIKEN cDNA 1700066M21 gene
  Adi1                                     -1,61       0,176     acireductone dioxygenase 1
  Tmem191c                                 -1,45       0,177     transmembrane protein 191C
  Gmnc                                     -2,55       0,177     geminin coiled-coil domain containing
  Zfp763                                   -1,51       0,182     zinc finger protein 763
  Slc25a18                                 -1,79       0,185     solute carrier family 25 (mitochondrial carrier), member 18
  Hhip                                     -2,01       0,185     Hedgehog-interacting protein
  Calb1                                    -1,51       0,185     calbindin 1
  Chst5                                    -1,74       0,185     carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5
  Trim59                                   -2,18       0,185     tripartite motif-containing 59
  Gpr34                                    -2,22       0,185     G protein-coupled receptor 34
  Olfml1                                   -2,24       0,185     olfactomedin-like 1
  Mturn                                    -1,41       0,185     maturin, neural progenitor differentiation regulator homolog (Xenopus)
  Gstm1                                    -1,80       0,185     glutathione S-transferase, mu 1
  Enho                                     -1,63       0,185     energy homeostasis associated
  Prodh                                    -1,86       0,185     proline dehydrogenase
  Slc27a1                                  -1,71       0,185     solute carrier family 27 (fatty acid transporter), member 1
  Pacsin3                                  -1,44       0,185     protein kinase C and casein kinase substrate in neurons 3
  Htr1a                                    -1,95       0,185     5-hydroxytryptamine (serotonin) receptor 1A
  Dll3                                     -1,72       0,187     delta like canonical Notch ligand 3
  Map6d1                                   -1,60       0,187     MAP6 domain containing 1
  Prrg1                                    -1,61       0,193     proline rich Gla (G-carboxyglutamic acid) 1
  Carns1                                   -1,88       0,201     carnosine synthase 1
  Tle2                                     -1,48       0,201     transducin-like enhancer of split 2
  Macrod1                                  -1,45       0,202     MACRO domain containing 1
  Nrgn                                     -1,51       0,204     neurogranin
  Plin3                                    -2,18       0,207     perilipin 3
  Grhpr                                    -1,38       0,208     glyoxylate reductase/hydroxypyruvate reductase
  Sult1a1                                  -2,19       0,214     sulfotransferase family 1A, phenol-preferring, member 1
  Pls1                                     -1,58       0,216     plastin 1 (I-isoform)
  Lin7b                                    -1,69       0,216     lin-7 homolog B (C. elegans)
  Armh4                                    -1,53       0,218     armadillo-like helical domain containing 4
  Panx2                                    -1,33       0,226     pannexin 2
  Appl2                                    -1,76       0,227     adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 2
  Grhl1                                    -1,01       0,227     grainyhead like transcription factor 1
  Tmem255b                                 -1,65       0,233     transmembrane protein 255B
  Pigz                                     -1,71       0,243     phosphatidylinositol glycan anchor biosynthesis, class Z

Differentially expressed genes in glia (FDR \< 0.25); logFC = log fold change; FDR = false discovery rate.

Results {#sec027}
=======

Quality control {#sec028}
---------------

Bisulfite conversion rates were above 98% (S1 Supplementary Information and [S3 Fig](#pone.0226575.s005){ref-type="supplementary-material"}) and multidimensional scaling plots of mRNAseq and RRBS data sets distinguished clearly between neurons and glia ([S4 Fig](#pone.0226575.s006){ref-type="supplementary-material"} and [S5 Fig](#pone.0226575.s007){ref-type="supplementary-material"}). The NeuN+ fraction enriched for neuronal and the NeuN- fraction for glial mRNA ([S6 Fig](#pone.0226575.s008){ref-type="supplementary-material"}), indicating a successful separation of neurons and glia.

Differential methylation {#sec029}
------------------------

A statistical analysis of Differentially Methylated CpGs (DM CpGs) compared right hippocampi of KA to SH mice at 24 hours post injection. After filtering, 928 430 CpG sites remained and were used in subsequent analyses. On average, across all CpG sites and all samples, each CpG was covered by 29.8 reads. In individual samples the mean read depth varied from 20.0 to 35.2 (median = 30.6, interquartile range = \[27.4--32.7\]).

### Differentially methylated sites {#sec030}

The analysis of significantly altered DM CpGs revealed 1060 hyper- and 899 hypomethylated (ratio 1.2:1) CpG sites in neurons and 464 hyper- and 274- hypomethylated (ratio: 1.7:1) CpG sites in glia ([Fig 1](#pone.0226575.g001){ref-type="fig"}). Most of the DM CpGs localized to either gene bodies or intergenic regions (for full list see supplementary 2) and were distributed evenly across chromosomes (sex chromosomes excluded), apart from a possible higher ratio of hyper-/hypomethylated CpGs at chromosome 13 to 15 in glia. The ratio of hypermethylated to hypomethylated CpG sites was highest at upstream (1.3:1) and intergenic (1.2:1) regions for neurons and upstream (2.7:1) and promoter (2.0:1) for glia. For detailed information including GO and KEGG annotation of DM CpGs see [S1 Table](#pone.0226575.s001){ref-type="supplementary-material"}.

![Differential DNA methylation at 24 hours post injection in the intracortical kainic acid model of mTLE.\
(A)--(C) Statistical analysis of differentially methylated CpGs (DM CpGs) of KA versus SH group, 24 hours post injection. (A) DM CpGs in neurons and glia; upward arrow indicates hypermethylation and downward arrow hypomethylation of DM CpGs. (B) Chromosomal distribution of DM CpGs. (C) Distribution of DM CpGs amongst genomic features. (D) Distribution of differentially methylated regions (DMR) amongst genomic features.](pone.0226575.g001){#pone.0226575.g001}

### Differentially methylated CpG sites common to both neurons and glia {#sec031}

Neurons and glia shared four commonly hypermethylated (fraction: 0.3%) and zero commonly hypomethylated DM CpGs. One DM CpG was hypermethylated in neurons and hypomethylated in glia (fraction: 0.0%) and one DM CpGs hypomethylated in neurons and hypermethylated in glia (fraction: 0.0%). Three of the four commonly hypermethylated DM CpGs localized to gene bodies and one to an upstream region of the associated gene. The other two CpGs were associated with intergenic regions.

### Differentially methylated regions {#sec032}

In order to obtain information about genomic features with significantly altered differential methylation, an aggregated analysis was conducted for each genomic feature (upstream, promoter, UTR5, exon, intron, gene body, UTR3) separately. Most DMR were found in gene bodies (e.g. exonic and intronic areas) and promoters in both neurons and glia. The greatest hyper-/hypomethylated regions ratio was found at 5'UTRs (ratio 4.5:1), gene bodies (ratio 3.7:1) and promoters (ratio 3.1:1) in neurons and at promoters (ratio 8.2:1), 3'UTRs (ratio 7.0:1) and exons (ratio 5.3:1) for glia. For a full list of significantly altered DMR and their annotated GO and KEGG terms see [S1 Table](#pone.0226575.s001){ref-type="supplementary-material"}.

Differential gene expression {#sec033}
----------------------------

DGE analysis compared right hippocampi of KA to SH at 24 hours post injection. After filtering, 23369 genes were used for downstream analysis. After processing, alignment and filtering, the mRNASeq samples yielded on average 7.5 giga bases (Gb) data aligned to the mouse genome (median = 9.0 Gb; range = \[2.4 Gb---13.0 Gb\]). The fraction aligning specifically to mRNA regions varied from 16% to 41.2% (median = 28.5), resulting in an average of 2.2 Gb per sample informative for DGE analysis (median = 2.2 Gb; range = \[0.4 Gb---4.3 Gb\]). In neurons, 135 genes were up- and 15 downregulated ([Table 1](#pone.0226575.t001){ref-type="table"}), while in glia 147 genes were up- and 85 downregulated ([Table 2](#pone.0226575.t002){ref-type="table"}). A relevant selection of broader GO / KEGG terms is presented in Tables [3](#pone.0226575.t003){ref-type="table"} (neurons) and [4](#pone.0226575.t004){ref-type="table"} (glia). For neuronal and glial contribution to epileptogenesis in terms of number of differentially expressed genes as part of epilepsy-relevant GO / KEGG terms, see [Fig 2](#pone.0226575.g002){ref-type="fig"}. For a detailed list of up- and downregulated genes and associated GO / KEGG terms see [S1 Table](#pone.0226575.s001){ref-type="supplementary-material"}.

![Number of up- and downregulated neuronal and glial genes within epilepsy-relevant functional annotation terms (GO / KEGG).\
Neuronal and glial contribution to epilepsy-relevant GO / KEGG pathways (p\<0.05) amongst differentially expressed genes. Negative values indicate downregulated genes, positive values upregulated genes.](pone.0226575.g002){#pone.0226575.g002}

10.1371/journal.pone.0226575.t003

###### Relevant GO and KEGG terms of up- and downregulated genes in neurons at 24 hours post injection in the intracortical kainic acid model of mTLE.

![](pone.0226575.t003){#pone.0226575.t003g}

                                                  Upregulated genes in neurons (N = 135)       Downregulated genes in neurons (N = 15)
  ----------------------------------------------- -------------------------------------------- -----------------------------------------
  **GO[\*](#t003fn002){ref-type="table-fn"}**     • Cell differentiation                       • Lymphocyte migration
  Signal transduction                             • Leukocyte migration                        
  • Cell death                                    • Endothelial cell proliferation             
  • Regulation of gene expression                 • Regeneration                               
  • Cell-cell signaling                           • Cellular response to DNA damage stimulus   
  • Cell surface receptor signaling               • Growth factor activity                     
  • Cell growth                                   • Vesicle organization                       
  **KEGG[\*](#t003fn002){ref-type="table-fn"}**   • ECM-receptor interaction                   
  • MAPK signaling                                                                             
  • IL17 signaling                                                                             
  • cAMP signaling                                                                             
  • TNF signaling                                                                              
  • VEGF signaling                                                                             
  • TGFbeta signaling                                                                          

Relevant GO and KEGG terms associated with significantly (FDR 0.25) upregulated genes

\* = p\<0.05.

10.1371/journal.pone.0226575.t004

###### Relevant GO and KEGG terms of up- and downregulated genes in glia at 24 hours post injection in the intracortical kainic acid model of mTLE.

![](pone.0226575.t004){#pone.0226575.t004g}

                                                  Upregulated genes in glia (N = 147)          Downregulated genes in glia (N = 85)
  ----------------------------------------------- -------------------------------------------- -------------------------------------------
  **GO[\*](#t004fn002){ref-type="table-fn"}**     • Regulation of IL1                          • Purinergic nucleotide receptor activity
  • Response to IL1                               • Regulation of ion transport                
  • MAPK                                          • PLC activating G-protein receptor          
  • Apoptotic process                             • NAD binding                                
  • Lymphocyte chemotaxis                         • Glutamate receptor signaling               
  • Cytokine production                           • Myelin sheath                              
  • Angiogenesis                                  • Mitochondrial part                         
  **KEGG[\*](#t004fn002){ref-type="table-fn"}**   • ECM-receptor interaction                   • Glutathione metabolism
  • MAPK signaling                                • Pyruvate metabolism                        
  • PI3K-Akt signaling pathway                    • ABC transporters                           
  • Cytokine-cytokine receptor interaction        • cAMP signaling pathway                     
  • TNF signaling                                 • Glycine, serine and threonine metabolism   
  • VEGF signaling                                                                             
  • JAK-stat signaling                                                                         

Relevant GO and KEGG terms associated with significantly (FDR 0.25) upregulated genes

\* = p\<0.05.

### Genes up- or downregulated in both neurons and glia {#sec034}

A total number of 45 genes were upregulated in both neurons and glia. GO terms of these included "positive regulation of transcription" and "cytokine mediated signaling" whilst KEGG terms contained "ECM receptor interaction", "VEGF-signaling" and "TNF-signaling". Three genes were downregulated in both neurons and glia.

Association between differential methylation and differential gene expression {#sec035}
-----------------------------------------------------------------------------

An association between DM and DGE was calculated by alignment of significantly altered DMR and differentially expressed genes (Combined FDR 0.25, for details see [S1 Table](#pone.0226575.s003){ref-type="supplementary-material"} and [S7](#pone.0226575.s009){ref-type="supplementary-material"}--[S20](#pone.0226575.s022){ref-type="supplementary-material"} Figs). No general correlation between DMR and DGE at various genomic features (upstream, promoter, UTR5, exon, intron, UTR3) was found ([S1 Table](#pone.0226575.s003){ref-type="supplementary-material"} and [S7](#pone.0226575.s009){ref-type="supplementary-material"}--[S20](#pone.0226575.s022){ref-type="supplementary-material"} Figs). However, significant DMR coincided with DGE at 41 loci for neurons and 12 loci for glia (Tables [5](#pone.0226575.t005){ref-type="table"} and [6](#pone.0226575.t006){ref-type="table"}).

10.1371/journal.pone.0226575.t005

###### Association between DMR and DGE in neurons at 24 hours post injection.

![](pone.0226575.t005){#pone.0226575.t005g}

              Neurons                                                                              
  ----------- ---------- ------- ----------------------------------------------------------------- --------------------------------------------------
  Upstream    *ZBTB18*   3,22    -1,20                                                             Zinc finger and BTB domain-containing protein 18
  *SPP1*      -0,99      3,14    Osteopontin                                                       
  Promoter    *SPP1*     -0,97   3,14                                                              Osteopontin
  *PDE6B*     -2,72      2,91    Rod cGMP-specific 3\',5\'-cyclic phosphodiesterase subunit beta   
  *BTG2*      5,23       1,49    Protein BTG2                                                      
  *DPYSL3*    4,70       1,02    Dihydropyrimidinase-related protein 3                             
  *GADD45G*   4,59       2,54    Growth arrest and DNA damage-inducible protein GADD45 gamma       
  *SCRT2*     3,77       1,43    Transcriptional repressor scratch 2                               
  Exon        *TRIB2*    4,72    1,20                                                              Tribbles homolog 2
  *ZFP36*     1,77       2,50    mRNA decay activator protein ZFP36                                
  *GAL*       2,13       3,64    Galanin                                                           
  *CXCL12*    -0,87      -1,96   Stromal cell-derived factor 1                                     
  *SV2C*      -1,27      2,56    Synaptic vesicle glycoprotein 2C                                  
  *GM5577*    3,67       -1,36   Predicted gene 5577                                               
  *LTBP1*     -1,11      1,48    Latent transforming growth factor beta binding protein 1          
  *ARL4D*     -0,61      1,61    ADP-ribosylation factor-like 4D                                   
  *FNDC9*     -1,07      3,19    Fibronectin type III domain-containing protein 9                  
  *CD34*      3,18       -1,63   Hematopoietic progenitor cell antigen CD34                        
  *EPHX1*     1,99       -1,28   Epoxide hydrolase 1                                               
  *TUBB6*     -0,51      1,49    Tubulin beta-6 chain                                              
  *BACH1*     -1,04      1,72    Fanconi anemia group J protein homolog                            
  Intron      *SAMD11*   0,73    2,19                                                              sterile alpha motif domain containing 11
  *KIF18A*    0,91       1,46    Kinesin-like protein KIF18A                                       
  *NPTX2*     -0,69      3,61    Neuronal pentraxin-2                                              
  *IGF2BP2*   -0,56      2,04    Insulin-like growth factor 2 mRNA-binding protein 2               
  *NPTX2*     -0,69      3,61    Neuronal pentraxin-2                                              
  Gene body   *KIF18A*   0,80    1,46                                                              Kinesin family member 18A
  *GAL*       2,09       3,64    Galanin peptides                                                  
  *TRIB2*     2,07       1,20    tribbles pseudokinase 2                                           
  *SAMD11*    0,70       2,19    Sterile alpha motif domain-containing protein 11                  
  *ADGRF4*    0,92       1,66    Adhesion G protein-coupled receptor F4                            
  *LTBP1*     -0,52      1,48    Latent-transforming growth factor beta-binding protein 1          
  *FAM129B*   -0,59      1,40    Niban-like protein 1                                              
  *IGF2BP2*   -0,54      2,04    insulin-like growth factor 2 mRNA binding protein 2               
  *CD34*      3,30       -1,63   CD34 antigen                                                      
  *SORCS3*    -0,40      2,28    VPS10 domain-containing receptor SorCS3                           
  *GXYLT2*    -0,85      1,40    Glucoside xylosyltransferase 2                                    
  *SV2C*      -0,63      2,56    Synaptic vesicle glycoprotein 2C                                  
  *ARL4D*     -0,60      1,61    ADP-ribosylation factor-like protein 4D                           
  UTR3        *EGR3*     3,45    1,61                                                              Early growth response protein 3
  *NEDD9*     -1,46      1,51    Enhancer of filamentation 1                                       

Genetic loci with coincidence of significant DM and DGE (FDR 0.25); logFC = log fold change.

10.1371/journal.pone.0226575.t006

###### Association between DMR and DGE in glia at 24 hours post injection.

![](pone.0226575.t006){#pone.0226575.t006g}

                    Glia                                                                          
  ----------------- ---------- ------- ---------------------------------------------------------- --------------------------------------------------
  Upstream          *ZBTB46*   -1,01   0,87                                                       Zinc finger and BTB domain-containing protein 46
  *KIRREL2*         3,75       -1,41   Kin of IRRE-like protein 2                                 
  *PANTR1*          -4,55      -1,72   POU3F3 Adjacent Non-Coding Transcript 1 (non coding RNA)   
  *ASCL1*           -4,05      -1,42   Achaete-scute homolog 1                                    
  Promoter          *HDAC11*   4,28    -1,42                                                      Histone deacetylase 11
  *DRD1*            4,24       1,62    D(1A) dopamine receptor                                    
  Exon              *ZFP467*   0,47    -1,38                                                      Zinc finger protein 467
  Intron            *DRD1*     4,17    1,62                                                       D(1A) dopamine receptor
  *2810468N07RIK*   -3,95      -2,22   RIKEN cDNA (lncRNA)                                        
  Gene body         *-*                                                                            
  UTR3              *FGFBP3*   3,75    -1,07                                                      Fibroblast growth factor-binding protein 3

Genetic loci with coincidence of significant DM and DGE (FDR 0.25); logFC = log fold change.

Discussion {#sec036}
==========

Neurons and glial cells execute specific complementary tasks in normal brain functioning as well as in the pathological processes precipitating neurological diseases \[[@pone.0226575.ref009], [@pone.0226575.ref048], [@pone.0226575.ref049]\]. This diversity is represented on the transcriptome- \[[@pone.0226575.ref036], [@pone.0226575.ref050]\] and epigenome level \[[@pone.0226575.ref034], [@pone.0226575.ref035]\]. In this study we investigated neuronal and glial alterations of DNAm and gene expression and their possible association in a mouse model of epilepsy. In order to explore the epigenetic and transcriptomic signature of both cell types in early epileptogenesis, we separated neurons and glia by FANS \[[@pone.0226575.ref051]\]. This approach was recently applied in epigenetic studies \[[@pone.0226575.ref039]--[@pone.0226575.ref041]\]. We identified specific neuronal and glial DNAm and DGE changes at particular genomic loci, potentially including important upstream mechanisms worth further investigation.

Differential methylation {#sec037}
------------------------

With an overlap of only 0.22% of DM CpGs between neurons and glia, differential methylation occurs primarily in a cell specific manner during early epileptogenesis. Accordingly, the attributed GO terms to DM CpGs and DMR reveal mostly neuronal and glia specific terms ([S1 Table](#pone.0226575.s001){ref-type="supplementary-material"}). Apart from a near even ratio at neuronal promoters, we observe an overweight of hypermethylated to hypomethylated CpG sites at 24 hours post injection. In early stages of epileptogenesis, previous studies suggest no general alteration of DNAm \[[@pone.0226575.ref030]\] or a tendency towards hypomethylation \[[@pone.0226575.ref052]\]. In chronic phases of epilepsy, both hyper- and hypomethylation have been reported \[[@pone.0226575.ref029], [@pone.0226575.ref053]\]. Differences in pro-convulsant agents, mode and region at which they are applicated, stage of epileptogenesis, anatomical regions investigated, as well as the number of CpG sites covered, may account for varying results. A comparison of genes associated with significant DM CpGs and DMR from our study with results from hippocampal tissue from chronic TLE patients \[[@pone.0226575.ref054]\] unvails marginal but interesting overlaps. This may be due to different methylation analysis methods and stage specific character of hippocampal DNAm during epileptogenesis. A comparison of our results to those from peripheral blood of TLE patients \[[@pone.0226575.ref055]\], reveals 15 overlapping DM CpGs and 11 overlapping DMRs.

Differential gene expression {#sec038}
----------------------------

Most differentially expressed genes detected in this study, were specific to either neurons or glia ([S1 Table](#pone.0226575.s001){ref-type="supplementary-material"}). Only 45 genes were commonly up- and three downregulated in neurons and glia. At this early stage of epileptogenesis, glial cells apparently contribute a higher number of altered gene transcripts than neurons within epilepsy-related GO and KEGG terms ([Fig 2](#pone.0226575.g002){ref-type="fig"}). Many significantly differentially expressed genes found in this epilepsy model overlap with data from other experimental and human TLE studies \[[@pone.0226575.ref029], [@pone.0226575.ref056]--[@pone.0226575.ref058]\]. Comparing our differentially expressed genes in neurons and glia with differential gene expression from various epilepsy models and stages of TLE \[[@pone.0226575.ref058]\], glia contributes with more upregulated gene transcripts (13 glia and 11 in neurons), supporting the notion that glia contributes essentially to epileptogenesis \[[@pone.0226575.ref059]--[@pone.0226575.ref066]\]. Neurons contribute with slightly higher number of altered gene transcripts when comparing to a amygdala stimulation model of epilepsy while glia contributes with a higher number of differentially expressed genes when comparing to a traumatic brain injury model of epilepsy \[[@pone.0226575.ref029]\]. Within up- and downregulated gene transcripts from a study on refractory human TLE, neurons and glia exhibit an almost even number of gene transcripts \[[@pone.0226575.ref057]\]. For an overview of essential up- and downregulated pathways see Tables [1](#pone.0226575.t001){ref-type="table"} and [2](#pone.0226575.t002){ref-type="table"}. A summary of neuronal and glial contribution (number of genes within a GO / KEGG term) to epileptogenesis is presented in [Fig 2](#pone.0226575.g002){ref-type="fig"}.

Altered epilepsy-relevant pathways based on differentially expressed genes {#sec039}
--------------------------------------------------------------------------

*Upregulation of growth arrest and DNA-damage-inducible beta/gamma* (GADD45B/G). One of the genes upregulated in both neurons and glia is *GADD45G*, a member of the environmental stress inducible *GADD45*-like genes that mediate activation of various pathways, including c-Jun N-terminal protein kinase family of mitogen-activated protein kinases \[[@pone.0226575.ref067]\]. It has previously been shown to be elevated after KA induced status epilepticus \[[@pone.0226575.ref068]\] and to possess DNA demethylation qualities \[[@pone.0226575.ref069]\], thus potentially linking epileptic activity to changes in DNA methylation. We also find elevated mRNA levels of *GADD45B*, which is another member of the *GADD45*-like genes. GADD45B has recently been shown to promote neuronal activity induced neurogenesis via demethylation of the BDNF and fibroblast growth factor promoter, linking neuronal activity to DNA methylation alterations \[[@pone.0226575.ref069]\].

*Upregulation of sphingosine-kinase 1* (SPHK1) *and sphingosine 1 receptor 3* (S1R3) {#sec040}
------------------------------------------------------------------------------------

Another interesting finding is the upregulation of *SPHK1* mRNA in neurons and glia. SPHK1 phosphorylates sphingosine to sphingosine-1-phosphate (S1P) \[[@pone.0226575.ref070]\]. S1P in turn is involved in neural development, signaling, autophagy and neuroinflammation as well as a plethora of pathological central nervous conditions \[[@pone.0226575.ref071]\] and has been shown to modulate histone deacetylase activity \[[@pone.0226575.ref072]\]. A recent study revealed antiepileptogenic effects of fingolimod \[[@pone.0226575.ref071]\], a SP1-receptor modulator and FDA approved drug for the treatment of multiple sclerosis \[[@pone.0226575.ref073]\], possibly via attenuation of astro- \[[@pone.0226575.ref074]\] and microglial \[[@pone.0226575.ref075]\] reactions. Further, we find elevated expression of *S1R3*, a S1P receptor, in glia. This receptor has been shown to be elevated in hippocampi of kainic acid and pilocarpine epilepsy models as well as in humans with TLE, and is mainly expressed in astrocytes \[[@pone.0226575.ref076]\].

Upregulated mitogen-activated protein kinase (MAPK) pathways in neurons and glia {#sec041}
--------------------------------------------------------------------------------

MAPK is a type of protein kinase specific to the amino acids serine and threonine. MAPKs are involved in directing cellular responses to a variety of different stimuli, such as proinflammatory cytokines, mitogens, osmotic stress and heat shock. They regulate cell functions including proliferation, gene expression and differentiation, mitosis, cell survival and apoptosis \[[@pone.0226575.ref077]\]. We find several genes within MAPK pathways (GO / KEGG) to be expressed more in the KA than SH group with glia contributing a higher number of differentially expressed genes within the pathways than neurons ([S1 Table](#pone.0226575.s001){ref-type="supplementary-material"}). In the context of epilepsy, MAPK are thought to play a role in Cx43 phosphorylation, involving TNF-α, interleukin (IL)-1b \[[@pone.0226575.ref078]\] and VEGF \[[@pone.0226575.ref079]\]. We find elevated expression levels of genes within KEGG pathways for both TNF-α (mostly in glia) and VEGF (slightly more in neurons, see [S1 Table](#pone.0226575.s001){ref-type="supplementary-material"}). Phosphorylation of Cx43 in turn has been associated with its elevated internalization and degradation \[[@pone.0226575.ref080]\], possible contributing to astrocyte uncoupling in both mTLE mice and humans \[[@pone.0226575.ref015]\].

*Astrocytic calcium signaling pathways altered in glia*. Neuronal activity induced elevations in astrocytic intracellular calcium levels may in turn facilitate astrocytic release of neuroactive substances including glutamate, aggravating epileptic activity \[[@pone.0226575.ref081]\]. In acute stages of epileptogenesis, calcium transients in astrocytes are increased, possibly contributing to elevated extracellular potassium levels via Calcium-dependent protease induced cleavage of the dystrophin associated protein complex \[[@pone.0226575.ref082], [@pone.0226575.ref083]\]. Elevated extracellular potassium levels in turn may lead to increased excitability of neurons and thereby generate epileptiform activity \[[@pone.0226575.ref084]\]. We also find elevated gene expression of inositol 1,4,5-trisphosphate 3-kinase A (*ITPKA*), a protein kinase inactivating inositol triphosphate dependent calcium release from the astrocyte endoplasmic reticulum \[[@pone.0226575.ref085], [@pone.0226575.ref086]\], in glia. Further, we find 1-Phosphatidylinositol-4,5-bisphosphate phosphodiesterase epsilon-1 (*PLCE1*), a member of the phosphatidylinositol-specific phospholipase C family that via G-protein coupled receptors are involved in Inositol-triphosphate and diacylglycerol generation and as such mediate intracellular Calcium elevation \[[@pone.0226575.ref087]\], elevated in glia. Thirdly, we find *CACNG5*, a calcium permissive AMPA receptor subunit \[[@pone.0226575.ref088]\], elevated in glia. Possibly all three genes mediate pro-epileptogenic effects via astrocytic calcium signaling. For a complete summary of differentially expressed genes see [S1 Table](#pone.0226575.s001){ref-type="supplementary-material"}.

Relationship between differential methylation and differential gene expression {#sec042}
------------------------------------------------------------------------------

We did not find a general correlation of DM and DGE at specific genomic regions ([S1 Table](#pone.0226575.s001){ref-type="supplementary-material"}, [S7](#pone.0226575.s009){ref-type="supplementary-material"}--[S20](#pone.0226575.s022){ref-type="supplementary-material"} Figs). However, DM coincided with DGE at 41 genes for neurons and 10 genes for glia. Our results are in line with previous studies that did not find a general correlation between DNA methylation and gene expression in epilepsy, but rather a number of singular genes where significant DM with DGE coincided \[[@pone.0226575.ref030], [@pone.0226575.ref089], [@pone.0226575.ref090]\]. Other studies did report a certain degree of general association between DM at specific genomic regions and DGE \[[@pone.0226575.ref029]\]. For a full list of coinciding alterations in DM and DGE see [Table 5](#pone.0226575.t005){ref-type="table"}. The identified coinciding alterations of DM and DGE in this study are relatively few and their role in epileptogenesis remains uncertain. Interestingly, they point to genes and pathways previously implicated in epilepsy, TLE and epileptogenesis. In the following we present a selection of these in depth.

### Coinciding alterations of differential methylation and differential gene expression in neurons {#sec043}

*Osteopontin* (SPP1) *promoter hypomethylation associated with elevated gene expression*. SPP1 mediates diverse aspects of cellular functioning in the central nervous system, e.g. the recruitment and activation of microglia and astrocytes, the cumulative effect possibly being neuroprotective \[[@pone.0226575.ref091]\]. In multiple sclerosis, SPP1 mediates pro-inflammatory pathways contributing to the relapse remission phenotype via e.g. NF-κB \[[@pone.0226575.ref092]\]. In our study, *SPP1* mRNA is significantly upregulated in both neurons and glia, and in neurons this elevated gene expression is associated with significant hypomethylation at the associated upstream region and promoter. These results confirm previous findings of elevated *SPP1* mRNA levels in epilepsy \[[@pone.0226575.ref093]\]. We further found elevated mRNA levels of *CD44*, a Osteopontin receptor \[[@pone.0226575.ref094]\] involved in epileptogenesis \[[@pone.0226575.ref095]\], in glia.

### *Hypermethylation at a Galanin* (GAL) *exon associated with elevated gene expression* {#sec044}

*GAL* encodes the neuropeptide Galanin which previously has been shown to possess seizure attenuating properties and discussed as a possible antiepileptogenic target \[[@pone.0226575.ref096]\]. Further, in a recent study, a de novo mutation in GAL has been unveiled as a possible cause for TLE \[[@pone.0226575.ref097]\].

In our study, *GAL* mRNA is significantly upregulated in both glia and neurons (slightly higher log fold change (logFC) and lower FDR in neurons) and we find a significant association of hypermethylation of an exonic region of *GAL* with elevated gene expression in neurons. Thus, the hypermethylation at the exonic region of *GAL* with possible consecutive elevated levels of GAL might represent a crucial endogenic seizure attenuating mechanism.

*Hypomethylation at synaptic vesicle protein 2 c* (SV2C) *exon associated with upregulated gene expression* {#sec045}
-----------------------------------------------------------------------------------------------------------

SV2C is, together with SV2A and SV2B, part of the family of synaptic vesicle proteins that are involved in Ca^2+^ dependent synaptic vesicle exocytosis and neurotransmission \[[@pone.0226575.ref098]\]. The most prominent epilepsy-related member, SV2A, is the main target through which levetiracetam and brivaracetam exert their antiepileptic and possibly antiepileptogenic effects \[[@pone.0226575.ref099]\]. In hippocampi of patients with chronic TLE, SV2C was the only of three synaptic vesicle proteins found to be significantly elevated. It was associated with mossy fiber sprouting and glutamatergic synapses and was proposed as a potential antiepileptogenic target \[[@pone.0226575.ref100]\]. Recent findings suggest a role of SV2C in the disruption of dopamine signaling in Parkinson's Disease \[[@pone.0226575.ref101]\]. At 24 hours post injection, we find elevated levels of *SV2C* mRNA in glia and neurons. In neurons this elevated gene expression is associated with significant hypomethylation of its exonic regions. Hypomethylation of the *SV2C* exon may thus exert upstream pro-epileptogenic effects.

Coinciding alterations of differential methylation and differential gene expression in glia {#sec046}
-------------------------------------------------------------------------------------------

*Promoter hypermethylation at* HDAC11 *associated with reduced gene expression levels*. In line with previous results \[[@pone.0226575.ref102]\], we find *HDAC11* mRNA levels decreased after SE. This reduced gene expression coincides with a significantly increased methylation at its associated promoter in glia. Reduced levels of *HDAC11* may cause an increased acetylation at H4 \[[@pone.0226575.ref103]\], previously shown to correlate with elevated levels of c-fos, c-jun and BDNF \[[@pone.0226575.ref104]\]. BDNF in turn has been associated with seizure-aggravating effects in acute phases of epileptogenesis \[[@pone.0226575.ref105]\] and higher levels of the microRNA miR-132, possibly via ERK and MAPK pathways \[[@pone.0226575.ref106]\]. Further, miR-132 has recently been associated with seizure induced neuronal apoptosis \[[@pone.0226575.ref107]\]. We find elevated expression levels of *BDNF* (only glia), miR-132 (both neurons and glia) and MAPK- (glia more transcripts than neurons) and ERK- (glia more than neurons) pathways in early epileptogenesis. The hypermethylation of the *HDAC11* promoter with its possible downstream effects ultimately leading to elevated levels of *BDNF* and miR-132 might represent a possible antiepileptogenic target for site specific alteration of DNAm.

### *Hypermethylation at the intron and promoter at dopamine receptor D1 (DRD1) associated with elevated* DRD1 *mRNA levels* {#sec047}

Dopamine exerts its seizure inducing effects via DRD1 mediated ERK1/2 pathways \[[@pone.0226575.ref108]\]. We find elevated levels of *DRD1* mRNA in both neurons and glia. In glia, this augmentation in gene expression is associated with significant hypermethylation in the intronic region and hypermethylation at the promoter of *DRD1*. Hypermethylation at glial *DRD1* (intronic region) may facilitate epileptogenesis.

Technical limitations {#sec048}
---------------------

This study features several technical limitations worth mentioning. Firstly, we cannot rule out that the NeuN- fraction contains a minor number of non-glial cells (pericytes, endothelial cells) \[[@pone.0226575.ref109], [@pone.0226575.ref110]\]. RRBS associated technical limitations involve loss of information associated with e.g. msp1 enzyme cleavage, library pooling/ fragment size selection, bisulfite conversion, sequencing (depth/coverage) \[[@pone.0226575.ref043]\]. The use of nuclear mRNA results in enrichment of mRNA coding for proteins with nuclear functions \[[@pone.0226575.ref111]\] and a potentially lower level of immediate early genes \[[@pone.0226575.ref112]\]compared to when using cytosolic mRNA \[[@pone.0226575.ref113]\].

Conclusion {#sec049}
==========

In this study, we found DNAm and DGE in early epileptogenesis to occur primarily in a cell-specific manner. We identified several potential neuronal and glial upstream targets worth further investigation. Information on the cellular origin of epigenomic and transcriptomic effects increases our understanding of involved pathological processes and provides a basis for possible future cell specific therapeutic approaches.

Supporting information {#sec050}
======================

###### DM and DGE in neurons and glia.

Table of significantly altered mRNA (RRBS) and DNA methylation (DM CpGs and DMR) in neurons and glia as well as overviews and adjunct functional annotations (GO / KEGG).

(XLSX)

###### 

Click here for additional data file.

###### Detailed methods.

(DOCX)

###### 

Click here for additional data file.

###### Flowchart of tissue processing from hippocampi to NeuN+ / NeuN- nuclei.

Hippocampi from Kainate (n = 8) or Sham (n = 8) animals at 24 hrs. after injection were pooled (sample 1: pooled 4 to 1; sample 2 and 3: pooled 2 to 1) and homogenized to obtain single nuclei. The nuclei were filtered, centrifugated, pelleted and resuspended, before being subjected to FANS.

(TIF)

###### 

Click here for additional data file.

###### 

**Sorting of NeuN-positive and NeuN-negative nuclei by flow cytometry (A--F) Nuclei were defined as PI-positive events, and aggregated nuclei were excluded in an SSC-w vs FSC-a plot.** Single nuclei from a tissue not expressing NeuN (adult mouse liver) were used to define the NeuN-positive and NeuN-negative gates (A), and hippocampal nuclei were sorted accordingly (B).

(TIF)

###### 

Click here for additional data file.

###### Estimated bisulfite conversion rates.

The left panel shows the PCT_NON_CPG_BASES_CONVERTED metric computed by Picard/CollectRRBSMetrics. This is defined as the fraction of converted cytosines among all non-CpG cytosines encountered in the sequencing data. The right panel shows the observed conversion rate of the unmethylated \"end-repair\" cytosines added in the RRBS prep (see [methods](#sec006){ref-type="sec"} for details).

(TIF)

###### 

Click here for additional data file.

###### Principal component analysis (MDS) of RRBS-Data.

The principal component analysis of RRBS data distinguishes clearly between neurons and glia but not between KA and SH.

(TIF)

###### 

Click here for additional data file.

###### Principal component analysis (MDS) of RNA-Data.

Principal component analysis of mRNAseq data clearly distinguished between neurons and glia as well as KA and SH.

(TIF)

###### 

Click here for additional data file.

###### Expression levels (mRNAseq, normalized counts) for CNS cell type specific genes.

Neurons: *RBFOX3* (= NeuN), Astrocytes: *ALDH1L1*, Microglia: *CX3CR1*, Oligodendrocytes: *MBP*, Pericytes: *PDGFRB*, Endothelial cells: *PECAM1*; Expression in the NeuN+ and NeuN- fraction on the left and right side of each graph.

(TIF)

###### 

Click here for additional data file.

###### DM and DGE (neurons, upstream).

Visualization of DM and DGE (FDR 0.25) for neurons (upstream). Genes associated with significantly altered DMR and DGE are indicated in the figure.

(TIF)

###### 

Click here for additional data file.

###### DM and DGE (glia, upstream).

Visualization of DM and DGE (FDR 0.25) for glia (upstream). Genes associated with significantly altered DMR and DGE are indicated in the figure.

(TIF)

###### 

Click here for additional data file.

###### DM and DGE (neurons, promoter).

Visualization of DM and DGE (FDR 0.25) for neurons (promoters). Genes associated with significantly altered DMR and DGE are indicated in the figure.

(TIF)

###### 

Click here for additional data file.

###### DM and DGE (glia, promoter).

Visualization of DM and DGE (FDR 0.25) for glia (promoters). Genes associated with significantly altered DMR and DGE are indicated in the figure.

(TIF)

###### 

Click here for additional data file.

###### DM and DGE (neurons, UTR5).

Visualization of DM and DGE (FDR 0.25) for neurons (UTR5). Genes associated with significantly altered DMR and DGE are indicated in the figure.

(TIF)

###### 

Click here for additional data file.

###### DM and DGE (glia, UTR5).

Visualization of DM and DGE (FDR 0.25) for glia (UTR5). Genes associated with significantly altered DMR and DGE are indicated in the figure.

(TIF)

###### 

Click here for additional data file.

###### DM and DGE (neurons, exon).

Visualization of DM and DGE (FDR 0.25) for neurons (exon). Genes associated with significantly altered DMR and DGE are indicated in the figure.

(TIF)

###### 

Click here for additional data file.

###### DM and DGE (glia, exon).

Visualization of DM and DGE (FDR 0.25) for glia (exon). Genes associated with significantly altered DMR and DGE are indicated in the figure.

(TIF)

###### 

Click here for additional data file.

###### DM and DGE (neurons, intron).

Visualization of DM and DGE (FDR 0.25) for neurons (intron). Genes associated with significantly altered DMR and DGE are indicated in the figure.

(TIF)

###### 

Click here for additional data file.

###### DM and DGE (glia, intron).

Visualization of DM and DGE (FDR 0.25) for glia (intron). Genes associated with significantly altered DMR and DGE are indicated in the figure.

(TIF)

###### 

Click here for additional data file.

###### DM and DGE (neurons, gene body).

Visualization of DM and DGE (FDR 0.25) for neurons (gene body). Genes associated with significantly altered DMR and DGE are indicated in the figure.

(TIF)

###### 

Click here for additional data file.

###### DM and DGE (glia, gene body).

Visualization of DM and DGE (FDR 0.25) for glia (gene body). Genes associated with significantly altered DMR and DGE are indicated in the figure.

(TIF)

###### 

Click here for additional data file.

###### DM and DGE (neurons, UTR3).

Visualization of DM and DGE (FDR 0.25) for neurons (UTR3). Genes associated with significantly altered DMR and DGE are indicated in the figure.

(TIF)

###### 

Click here for additional data file.

###### DM and DGE (glia, UTR3).

Visualization of DM and DGE (FDR 0.25) for glia (UTR3). Genes associated with significantly altered DMR and DGE are indicated in the figure.

(TIF)

###### 

Click here for additional data file.
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PLOS ONE

Dear Dr. Berger,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Oct 25 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Giuseppe Biagini, MD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Manusript by Berger et al. describes alterations in DNA methylation and gene expression in neurons and glia separately at 24h fllowing status epilepticus. Subject is very timely and of interest for many readers. Data are presented in details which enables readers to dig into particular molecular events of interest for them. I do not have any serious critical comments.

Minor issues:

\- do animals in intracortical KA model develop epilepsy?

\- tables 1-2 may be misleading since cells in rows do not present the same or similar categories but from different databases as it might be interpreted by reader

\- does the method used by authors allow maintaining cell integrity during homogenization of frozen tissue, or is cytoplasm lost and only morre resistant nuclei are sorted?

Reviewer \#2: Review to manuscript PONE-D-19-20265

In the present study, Berger et al. describe cell population specific DNA methylation and gene expression in mice (n=8 per group, KA and sham respectively), 24h following status epilepticus from intracortical (juxta-hippocampal) Kainic acid injection. FANS was used to sort NeuN-positive and NeuN-negative nuclei from pooled HC. DNA and total RNA were extracted and used for sequencing. The experimental design and data are mainly well described, however the following comments remain:

1\. Neuronal and non-neuronal nuclei were isolated, not whole cells. NeuN-negative nuclei, do not necessarily have to originate from glial cells. As nuclei were sorted and analyzed not all transcription was studied, but only immediate transcripts that were still present in the nucleus. The preparation method was also not mRNA-specific, but total RNA was extracted. The reviewer is aware of the technical limitations for single cell-sequencing from adult brain tissue and thus only requests that the authors are specific about their methodology to not confuse the reader.

2\. p9: „For any gene, its promoter region was defined as the 1 kb segment immediately upstream of the transcription start site and the upstream region from -5 kb to -1 kb, where negative numbers indicate positions upstream of transcription start site." Unclear. So the promoter definition was -1kb from TSS and the upstream region is -1kb to -5kb? Please explain why the „upstream region" was considered interesting? What function it is supposed to have in gene regulation?

3\. Authors should make sequencing data (raw files) available through GEO.

4\. The authors state "We detected single genetic loci in several epilepsy-related genes, where DNAm and GE changes coincide. These may serve as potential target sites for epigenetic antiepileptogenic therapeutic intervention." However, the number of differentially methylated CpGs/regions that correlated with gene expression was very low. Also the time point 24h after SE is very short. At this stage the acute response to the KA treatment and status is visible, which has little to do with the later epileptogenic process and questions the suitability of suggested targets for therapeutic interventions in chronic epilepsy. In general, this reviewer feels that the discussion of single genes from the present data overestimates the results. Rather, a discussion of technical limitations should be included.

5\. Much information appears to be hidden in the supplements.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Manuscript number: PONE-D-19-20265

Title: Neuronal and glial DNA methylation and gene expression changes in early epileptogenesis

Dear Editor Professor Biagini,

We thank you for the expert reviews on our paper!

Based on the helpful comments of the reviewers, we have now prepared a revised and expanded version of our manuscript. In our opinion, the revision has improved our paper and we trust that you will find the new version suitable for publication in PLOS ONE.

Below are our responses to the reviewers' comments.

Reviewer \#1: Manuscript by Berger et al. describes alterations in DNA methylation and gene expression in neurons and glia separately at 24h following status epilepticus. Subject is very timely and of interest for many readers. Data are presented in detail which enables readers to dig into particular molecular events of interest for them. I do not have any serious critical comments.

Minor issues:

\- do animals in intracortical KA model develop epilepsy?

We want to thank reviewer 1 for the positive review.

The answer to the question from reviewer 1 is YES. More than 90% of animals treated with intracortical kainic acid develop epilepsy, as characterized in detail by Bedner P. et al., in the journal Brain in 2015. This is further confirmed by our own experience with the model (Szokol K. et al., Front Exp Neurosci, 2015). Accordingly, a more thorough description of the KA model has been added in the revised manuscript (methods).

\- tables 1-2 may be misleading since cells in rows do not present the same or similar categories but from different databases as it might be interpreted by reader

We agree with reviewer 1 and changed the tables 1 and 2 (now tables 3 and 4) accordingly. We think that they now provide a better overview of GO- and KEGG terms in neuronal and glial up- and downregulated genes.

\- does the method used by authors allow maintaining cell integrity during homogenization of frozen tissue, or is cytoplasm lost and only more resistant nuclei are sorted?

Our method represents a modified variant of Jiang et al., BMC Neurosci, 2008 and is based on sorting of cell nuclei, which has several advantages over cell based sorting (e.g. as stated nuclei are more resistant than whole cells; Grindberg R. et al., PNAS, 2013). Consequently, cytoplasm and its contents are lost. This is already specified in the methods section and has now also been revised in the abstract as well as added to the new technical limitations chapter.

Reviewer \#2: Review to manuscript PONE-D-19-20265

In the present study, Berger et al. describe cell population specific DNA methylation and gene expression in mice (n=8 per group, KA and sham respectively), 24h following status epilepticus from intracortical (juxta-hippocampal) Kainic acid injection. FANS was used to sort NeuN-positive and NeuN-negative nuclei from pooled HC. DNA and total RNA were extracted and used for sequencing. The experimental design and data are mainly well described, however the following comments remain:

1\. Neuronal and non-neuronal nuclei were isolated, not whole cells. NeuN-negative nuclei, do not necessarily have to originate from glial cells.

As nuclei were sorted and analyzed not all transcription was studied, but only immediate transcripts that were still present in the nucleus.

The preparation method was also not mRNA-specific, but total RNA was extracted. The reviewer is aware of the technical limitations for single cell-sequencing from adult brain tissue and thus only requests that the authors are specific about their methodology to not confuse the reader.

First, we want to thank reviewer 2 for the in-depth review.

Reviewer 2 is right regarding the NeuN- fraction containing a small number of other cell types than glia. In the revised manuscript, we now have specified this in a new section on technical limitations.

Regarding RNA sequencing, we first isolated total RNA from sorted nuclei. The consecutive step of using a oligo(dT) primer for cDNA creation sub selects mRNA transcripts. We agree with reviewer 2 that this has not been pointed out clearly in the article. We have now adjusted nomenclature and added details in the methods section of the revised manuscript for clarification (methods, supplementary methods). Concerning the use of nuclear mRNA, we are aware of technical limitations like enrichment of mRNA coding for proteins with nuclear functions (Barthelson RA et al., BMC Genomics, 2007) and a potentially lower level of immediate early genes (Bakken TE et al., PLOS ONE, 2018) compared to cytosolic mRNA. This has now been added to the discussion (technical limitations).

2\. p9: „For any gene, its promoter region was defined as the 1 kb segment immediately upstream of the transcription start site and the upstream region from -5 kb to -1 kb, where negative numbers indicate positions upstream of transcription start site." Unclear. So the promoter definition was -1kb from TSS and the upstream region is -1kb to -5kb? Please explain why the „upstream region" was considered interesting? What function it is supposed to have in gene regulation?

We thank the reviewer for the insightful feedback. Regarding the definition of genomic regions, we have modified our formulations in the paper (methods). As correctly stated, the upstream region was defined as from -5kb to -1kb and promoter region from -1kb to TSS.

Concerning the use of the upstream region as a separate genomic feature, we used predefined genomic feature types supplied by the annotatr package in R, having no à priori hypothesis of possible importance of genomic feature types per se.

3\. Authors should make sequencing data (raw files) available through GEO.

RAW files have now been uploaded to GEO (GSE138100).

4\. The authors state "We detected single genetic loci in several epilepsy-related genes, where DNAm and GE changes coincide. These may serve as potential target sites for epigenetic antiepileptogenic therapeutic intervention." However, the number of differentially methylated CpGs/regions that correlated with gene expression was very low. Also the time point 24h after SE is very short. At this stage the acute response to the KA treatment and status is visible, which has little to do with the later epileptogenic process and questions the suitability of suggested targets for therapeutic interventions in chronic epilepsy.

Several animal models of temporal lobe epilepsy have shown that important cellular/molecular changes already occur during the first hours and days after status epilepticus (Bedner P. et al., Brain, 2015; Rakhade SN et Jensen FE, Nat Rev Neurol. 2009). In this model, the latent phase of epilepsy starts after around 4 hours (post injection) and lasts 5+-2.9 days (see also figure below). We therefore believe that 24 hours post injection is an appropriate time point for studying early epigenetic mechanisms and gene expression precipitating downstream molecular changes. We agree with reviewer 2 that it also would be of high interest to study DNA methylation and gene expression at a later time point reflecting a chronic stage of epileptogenesis.

Figure: Epileptogenesis in the intracortical kainic acid model of mTLE (modified from Bedner P. et al., Brain, 2015)

In general, this reviewer feels that the discussion of single genes from the present data overestimates the results. Rather, a discussion of technical limitations should be included.

We are aware of the limitations and restricted interpretability of a few genomic loci at one time point and have revised the discussion accordingly as well as added a new section on technical limitations. We want to thank reviewer 2 for the critical feedback, as this surely will increase the quality of this paper.

5\. Much information appears to be hidden in the supplements.

We have integrated the list of differentially expressed genes (up- and downregulated genes) as Tables 1 and 2 into the revised manuscript (numbers of the previous tables have been adjusted).

With kind regards,

Toni Berger

###### 
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Click here for additional data file.
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Dear Dr. Berger,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the following points:

- Indicate how animals were killed.

\- Provide a section describing statistics in methods.

\- Check tables for values\' unit (thousands).

We would appreciate receiving your revised manuscript by Jan 04 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Giuseppe Biagini, MD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: no further comments

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0226575.r004
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Dear Editor Professor Biagini,

We thank you for your feedback regarding our paper:

\- Indicate how animals were killed.

\- Provide a section describing statistics in methods.

\- Check tables for values\' unit (thousands).

All three points have been addressed and the manuscript adjusted accordingly.

We hope that you will find the new version suitable for publication in PLOS ONE.

With kind regards,

Toni Berger
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Dear Dr. Berger,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Giuseppe Biagini, MD

Academic Editor

PLOS ONE
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Neuronal and glial DNA methylation and gene expression changes in early epileptogenesis

Dear Dr. Berger:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Giuseppe Biagini

Academic Editor

PLOS ONE
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